Navigation Links
Registry: Do medications which reduce angina
Date:8/30/2011

Although medication which decreases the risk of angina attacks (chest pain caused by blockage of the arteries that supply the heart), are frequently prescribed in patients who have sustained a myocardial infarction, the possible influence of medication on long-term survival is not known, with the exception of beta-blocking agents, which have been shown to decrease mortality in clinical trials performed 30 years ago. Because antianginal drugs also protect the myocardium against ischemia (insufficient oxygen delivery to the heart muscle), there is a possibility that they may improve the prognosis of patients having suffered a heart attack. There are several classes of antianginal medications, which act through different mechanisms and therefore may have different effects on the clinical prognosis of patients.

The French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction (FAST-MI), is a nationwide survey of patients hospitalised for acute myocardial infarction in France over a one-month period, at the end of 2005. Patients included will be followed for a period of 10 years after the initial heart attack. At three years, fewer than 5% of the patients have been lost to follow-up.

Of a population of 3,670 patients included in the registry, 3,262 survived the initial hospitalisation and had a complete prescription at discharge. Among them, 1266 (39%) received antianginal agents other than beta-blockers. Calcium-channel blockers were prescribed to 16% (dihydropyridines 10.5%, diltiazem 2% or verapamil 3%), nitrates to 19%, molsidomine to 3%, nicorandil to 9% and trimetazidine to 4.5% of patients. In addition, beta-blockers were prescribed to 77% of the patients. Patients who received antianginal agents were older and had more severe infarctions than those who did not receive such medications.

Three-year survival was 77% in patients treated with antianginal agents, compared with 86% in those who were not. After taking into account the initial profile of the patients and the severity of their heart attacks, prescription of antianginal medications was associated with a small (7%), non significant increase in the risk of dying in the 3 years following the heart attack.

When the different antianginal agents were analysed individually, none was associated with either a decreased or an increased risk of dying, except for molsidomine. Prescription of nitrates, the most ancient antianginal medication available, was associated with a trend to increased risk of death (+ 22%) which was not statistically significant; molsidomine was prescribed in a small number of patients (n=111) and was associated with a significant excess of deaths (+ 57%).

There was no evidence of any benefit or harm with respect to long-term mortality with most antianginal agents prescribed in patients having sustained a heart attack. The findings of possible increased hazard associated with use of nitrates, and more importantly of molsidomine, are intriguing and deserve further studies.


'/>"/>

Contact: Jacqueline Partarrieu
press@escardio.org
33-633-473-335
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. Excessive Heat Can Harm Medications, Expert Says
2. Pivotal study in Africa finds that HIV medications prevent HIV infection
3. No increase in severe cardiovascular events for children, adolescents taking ADHD medications
4. Researchers report widespread use of medications among pregnant women
5. Evidence Weak to Support Many Medications for Autism: Study
6. Massachusetts General Hospital leading nationwide, comparative study of common bipolar medications
7. Instructions on over-the-counter medications for children are found to be confusing
8. Missed opportunities: Most heart attack patients are not taking preventive medications
9. Medications found to cause long term cognitive impairment of aging brain
10. Psychotropic medications can cause birth defects
11. Publix Pharmacy Now Offers Pill Glide, an Innovative New Way for Children and Adults to Take Vitamins, Supplements and Medications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... , ... Many families have long-term insurance that covers care for a family ... for care if the client has a cognitive impairment diagnosis. , “What this ... often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, owner ...
(Date:10/13/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has ... least understood books in the Holy Scriptures, Revelation. The Book of Revelation paints a ... centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins says that ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian ... On The Brink” is the creation of published author, William Nowers. Captain Nowers ... a WWII veteran, he spent thirty years in the Navy. Following his career ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about ... intend to develop to enable prevention of a major side effect of chemotherapy ... especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host ... webcast on Friday, November 3, 2017, beginning at 7:00 ... approximately 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... performance and guidance for 2018, Hill-Rom executives will also ... performance, and long-range financial outlook through 2020. ...
Breaking Medicine Technology: